A UPenn research team has developed a proof-of-principle detection platform that uses microbubbles to make target protein molecules visible and detectable.
Isoma, which launched last year, will use the funds to develop and clinically validate a molecular test for stratifying glioblastoma patients.
A year-long clinical trial at three hospitals found that price transparency alone may not lead to significant changes in a clinician's test requests.
Research using the T2Plex instrument has detected a new conformation of red blood cells indicating a tight clot, which could be used as a biomarker.
The device, which will be tested in collaboration with a Panamanian research institute, will run 40-minute tests without the need for electricity.
